| 摘要 |
<p>The invention relates to medicine, particularly to pediatric hepatology and infectious diseases and can be used for treating chronic viral hepatitis B with cholestatic syndrome in children.Summary of the invention consists in that it is performed the basic treatment, and simultaneously is administered per os 5α-furostan-3β,22,26-triol-3-[O-β-D-glucopyranosyl(1→2)-β-D-glucopyranosyl(1→4)-β-D-galactopyranosyl]-26-O-β-D-glucopyranoside 100 mg, 2 times a day, 3-O-[β-D-glucopyranosyl(1→2)]-[β-D-glucopyranosyl(1→3)]-[β-D-glucopyranosyl(1→4)]-β-D-galactopyranosyl[(25R)-5α-furostan-2α,3β,22α,26-tetraol]-26-O-β-D-glucopyranoside 50 mg and ursodesoxycholic acid 15 mg/kg body weight, once a day, for 24 weeks.</p> |
